ImmunityBio (NASDAQ:IBRX) Given “Buy” Rating at D. Boral Capital

D. Boral Capital reiterated their buy rating on shares of ImmunityBio (NASDAQ:IBRX) in a report issued on Monday,Benzinga reports. They currently have a $23.00 price target on the stock.

IBRX has been the subject of several other research reports. HC Wainwright upped their price objective on shares of ImmunityBio from $8.00 to $10.00 and gave the stock a “buy” rating in a research report on Monday, January 26th. Piper Sandler boosted their target price on shares of ImmunityBio from $5.00 to $7.00 and gave the company an “overweight” rating in a research report on Tuesday, January 20th. Weiss Ratings reiterated a “sell (e+)” rating on shares of ImmunityBio in a research report on Monday, December 29th. Jefferies Financial Group lifted their price objective on shares of ImmunityBio from $8.00 to $9.00 and gave the company a “buy” rating in a research note on Friday, December 12th. Finally, BTIG Research upped their target price on ImmunityBio from $6.00 to $9.00 and gave the stock a “buy” rating in a research note on Thursday, January 22nd. Six research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $12.60.

ImmunityBio Price Performance

Shares of NASDAQ:IBRX opened at $9.83 on Monday. The business’s 50 day simple moving average is $4.63 and its 200 day simple moving average is $3.17. ImmunityBio has a 1 year low of $1.83 and a 1 year high of $11.00. The company has a market capitalization of $9.68 billion, a P/E ratio of -23.98 and a beta of 0.14.

ImmunityBio (NASDAQ:IBRX) last announced its quarterly earnings data on Monday, March 2nd. The company reported ($0.06) earnings per share for the quarter, beating the consensus estimate of ($0.08) by $0.02. The company had revenue of $38.29 million during the quarter. On average, sell-side analysts anticipate that ImmunityBio will post -0.92 EPS for the current fiscal year.

Insider Buying and Selling

In related news, Director Barry J. Simon sold 151,967 shares of the stock in a transaction that occurred on Tuesday, January 20th. The shares were sold at an average price of $7.20, for a total value of $1,094,162.40. Following the completion of the transaction, the director owned 3,091,604 shares of the company’s stock, valued at $22,259,548.80. This represents a 4.69% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Christobel Selecky sold 50,000 shares of the firm’s stock in a transaction that occurred on Friday, January 16th. The shares were sold at an average price of $5.00, for a total transaction of $250,000.00. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 226,967 shares of company stock valued at $1,531,912. 69.48% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On ImmunityBio

Hedge funds and other institutional investors have recently bought and sold shares of the company. Slow Capital Inc. bought a new position in ImmunityBio in the third quarter valued at about $25,000. Envision Financial Planning LLC bought a new stake in shares of ImmunityBio during the second quarter worth about $28,000. Summit X LLC acquired a new position in shares of ImmunityBio in the second quarter valued at approximately $28,000. Diversify Advisory Services LLC bought a new position in ImmunityBio in the 2nd quarter valued at approximately $27,000. Finally, Truist Financial Corp bought a new position in ImmunityBio in the 3rd quarter valued at approximately $27,000. Institutional investors own 8.58% of the company’s stock.

Key Headlines Impacting ImmunityBio

Here are the key news stories impacting ImmunityBio this week:

• Positive Sentiment: Q4 revenue surge — ImmunityBio reported roughly 700% year‑over‑year revenue growth driven by ANKTIVA commercial sales and cited expanded ANKTIVA approvals (including lung cancer) and global commercial partnerships in ~33 countries — a clear revenue catalyst. ImmunityBio, Inc.: ImmunityBio Reports 700% Year-Over-Year Revenue Growth, Expanded ANKTIVA Approvals in Lung Cancer and Global Commercial Partnerships
• Positive Sentiment: Earnings beat — Q4 loss per share was $0.06 vs. the consensus loss of $0.08 (and improved from a $0.15 loss a year ago); revenue of ~$38.28M topped estimates, signaling improving economics as ANKTIVA sales ramp. ImmunityBio (IBRX) Reports Q4 Loss, Beats Revenue Estimates
• Positive Sentiment: Analyst support — D. Boral Capital reaffirmed a “buy” rating and set a $23 price target, indicating strong bullish sentiment from at least one sell‑side shop and potentially supporting further upside if execution continues. Benzinga coverage of analyst rating
• Neutral Sentiment: Investor visibility event — Founder Dr. Patrick Soon‑Shiong will speak at the Milken Institute & Richard Nixon Foundation “Cancer 2035” summit; this raises profile and could help outreach but has no immediate operational impact. ImmunityBio Founder Dr. Patrick Soon-Shiong to Speak at Milken Institute and Richard Nixon Foundation “Cancer 2035” Summit
• Neutral Sentiment: Management commentary — Chairman teased a 3‑year expansion plan for ANKTIVA and hinted at potential breakthroughs; bullish messaging can support sentiment but is forward‑looking and execution‑dependent. IBRX stock to open week on a high? Chairman teases Anktiva’s 3-year expansion plans
• Negative Sentiment: Profitability risk remains — despite the beat, ImmunityBio is still operating at a loss and consensus estimates show negative EPS for the year (the company’s valuation depends heavily on ANKTIVA scaling and further approvals). ImmunityBio Q4 press release / financials

ImmunityBio Company Profile

ImmunityBio, Inc is a clinical-stage biotechnology company specializing in the development of novel immunotherapies for cancer and infectious diseases. The company’s research platform centers on harnessing the power of the human immune system—through engineered T cells, natural killer (NK) cells, cytokine superagonists and viral-vectored vaccines—to target and eliminate diseased cells across a range of indications.

Among its lead assets is Anktiva (formerly known as N-803), an interleukin-15 superagonist designed to stimulate NK and T cell activity.